EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Approach to the Patient With Dopamine-Resistant Microprolactinoma

Andrea Glezer iD, Matheo Augusto Morandi Stumpf iD, Nara Lima Queiroz iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf624 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Andrea Glezer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo 05403-010, Br…. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms, Dopamine Agonists, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 157 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolactinoma is a significant cause of hyperprolactinemia and the most common type of pituitary tumor. Women of fertile age are most commonly affected, and the clinical picture is characterized by galactorrhea, oligo-amenorrhea, and infertility. In microprolactinomas, which represent more than 60% of cases in women before menopause, there is usually no concern about the mass effect. Therefore, management can be expectant if there are no symptoms or in a patient in the postmenopausal period; oral contraceptive in the presence of hypogonadism and no desire for pregnancy; dopamine agonist (DA) in the presence of bothersome galactorrhea, hypogonadism, and the desire for fertility; and neurosurgery in selected noninvasive cases. Resistance to DA occurs in less than 10% of cases. Although the reduction in dopamine receptor subtype 2 expression is considered the primary cause of DA resistance, the underlying mechanisms are not yet completely elucidated. The main concern in resistant cases is the risk of symptomatic tumor growth during assisted reproduction techniques and pregnancy. Other conditions in which hyperprolactinemia could be implicated, such as metabolic parameters, osteoporosis, and breast cancer risk are also discussed. Understanding the mechanisms of DA resistance can lead to the opening of new treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaPituitary NeoplasmsDopamine AgonistsDrug Resistance, NeoplasmHumansFemaleHyperprolactinemiaPregnancy

Stichwörter der Autor:innen

cabergolinedopamine agonisthyperprolactinemiamicroprolactinomaneurosurgerypregnancy

Substanzen

Dopamine Agonists

Autor:innen und Institutionen

  • Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School, Sao Paulo 05403-010, Brazil.

ORCID-Profile: Andrea Glezer, Matheo Augusto Morandi Stumpf, Nara Lima Queiroz

Zitieren

APA

Glezer, A., Stumpf, M. A. M., & Queiroz, N. L. (2026). Approach to the Patient With Dopamine-Resistant Microprolactinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf624

Vancouver

Glezer A, Stumpf MAM, Queiroz NL. Approach to the Patient With Dopamine-Resistant Microprolactinoma. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf624

BibTeX
@article{Glezer2026,
  author = {Glezer, Andrea and Stumpf, Matheo Augusto Morandi and Queiroz, Nara Lima},
  title = {Approach to the Patient With Dopamine-Resistant Microprolactinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf624}
}
Kostenlos starten →